Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25793819 | 1.00 | IRAK4 (0.42) | IRAK4DPP4CCNCCDK8CYP3A4 | |
| SCHEMBL25291399 | 0.83 | MIF (0.35) | IRAK4CYP3A4 | |
| SCHEMBL31489919 | 0.75 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL25251614 | 0.75 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL30427652 | 0.68 | POLB (0.44) | IRAK4 | |
| SCHEMBL25249176 | 0.68 | POLB (0.44) | IRAK4 | |
| SCHEMBL25930990 | 0.68 | CA12 (0.46) | DPP4CCNCCDK8CYP3A4CDK19 | |
| SCHEMBL29468237 | 0.68 | CA12 (0.46) | DPP4CCNCCDK8CYP3A4CDK19 | |
| SCHEMBL757937 | 0.67 | CYP3A4 (0.51) | DPP4CCNCCDK8CYP3A4TTR | |
| SCHEMBL757936 | 0.67 | CYP3A4 (0.51) | DPP4CCNCCDK8CYP3A4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074919-A1 | Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2025-03-06 | — | — | US | disclosed |
| EP-4456895-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | Accro Bioscience (HK) Limited (HK) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023130054-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074919-A1 | Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885DPP4 316/4885CCNC 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.